Johnson & Johnson

Latest Headlines

Latest Headlines

J&J steps in with a $509M-plus deal to partner on a tau vaccine for Alzheimer's

After diving deep into the amyloid beta theory on Alzheimer's and coming up empty-handed--so far--Johnson & Johnson is partnering with Switzerland's AC Immune on an early-stage therapeutic vaccine that targets tau tangles as a prime suspect in triggering the memory-wasting ailment.

How much for docs speaking on Eliquis, Xarelto and Pradaxa? $20M and counting

If you've watched television lately, you know that Pfizer and Bristol-Myers have been spending a lot of money on advertising to back their new anticoagulant, Eliquis. So have rival Boehringer Ingelheim, with its Pradaxa drug, and Bayer and Johnson & Johnson with Xarelto.

Valneva picks up J&J's cholera vaccine--and some forthcoming competition

Johnson & Johnson's Crucell is officially out of the cholera space, and France's Valneva is in. And that means it's Valneva that's about to inherit some hefty competition that's coming up through its rivals' pipelines.

Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late?

Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J's candidate come too late to catch up with its rivals and help combat the current epidemic?

J&J inks an $835M RNA deal to develop autoimmune drugs with Isis

You can now count Johnson & Johnson among the roster of big companies to ally itself with Isis Pharmaceuticals' R&D group. J&J has stepped up with an $835 million pact to develop new drugs for autoimmune diseases of the gastrointestinal tract with the RNA specialists at Isis.

Get ready to negotiate, drugmakers: Payers are armed for drug-pricing battle

If 2014 was the year of the emboldened U.S. payer, then 2015 promises to be the year of the pharma negotiator.

Biotech goes global as Asia gets connected with the U.S. and Europe

In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.

J&J inks an antibody discovery deal with Sevion

The J&J Innovation center in California has helped orchestrate a deal with San Diego-based Sevion Therapeutics to develop new antibodies for a Janssen affiliate, CNA Development.

J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration

Johnson & Johnson and Lundbeck are throwing some scientific muscle behind a new initiative at the Wellcome Trust which enlisted researchers at 7 top academic research institutions in an effort to determine what role the immune system and inflammation play in depression and neurodegenerative diseases like Alzheimer's.

UPDATED: J&J steps up with $700M deal for MacroGenics' blood cancer drug, shares spike

Johnson & Johnson is fronting $125 million to gain the worldwide license on a bispecific cancer drug from MacroGenics, with up to $575 million more promised in prospective milestones for a successful development program. And the biotech says that the deal marks the beginning of a new program for a drug designed to stir a T cell attack against blood cancers.